Virios Therapeutics Statistics
Share Statistics
Virios Therapeutics has 1.33M
shares outstanding. The number of shares has increased by -95.2%
in one year.
| Shares Outstanding | 1.33M |
| Shares Change (YoY) | -95.2% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 5.12% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 12,075 |
| FTD / Avg. Volume | 13.75% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -50.98 and the forward
PE ratio is null.
Virios Therapeutics's PEG ratio is
0.68.
| PE Ratio | -50.98 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 70.92 |
| P/FCF Ratio | -55.44 |
| PEG Ratio | 0.68 |
Financial Ratio HistoryEnterprise Valuation
Virios Therapeutics has an Enterprise Value (EV) of 266.68M.
| EV / Sales | 0 |
| EV / EBITDA | 1767.23 |
| EV / EBIT | -54.75 |
| EV / FCF | -54.75 |
Financial Position
The company has a current ratio of 11.62,
with a Debt / Equity ratio of 0.
| Current Ratio | 11.62 |
| Quick Ratio | 11.62 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -139.12% and Return on Invested Capital is -142.93%.
| Return on Equity | -139.12% |
| Return on Assets | -127.14% |
| Return on Invested Capital | -142.93% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,324,003.75 |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -5.45K |
| Effective Tax Rate | 0.1% |
Stock Price Statistics
The stock price has increased by -98.59% in the
last 52 weeks. The beta is 1.58, so Virios Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.58 |
| 52-Week Price Change | -98.59% |
| 50-Day Moving Average | 4.41 |
| 200-Day Moving Average | 7.21 |
| Relative Strength Index (RSI) | 51.55 |
| Average Volume (20 Days) | 87,787 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.45M |
| Net Income | -5.3M |
| EBITDA | 150.9K |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.28 |
Full Income StatementBalance Sheet
The company has 3.32M in cash and 0 in
debt, giving a net cash position of 3.32M.
| Cash & Cash Equivalents | 3.32M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -61.47M |
| Total Assets | 3.64M |
| Working Capital | 3.14M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -4.87M
and capital expenditures 0, giving a free cash flow of -4.87M.
| Operating Cash Flow | -4.87M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.87M |
| FCF Per Share | -0.26 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
